bpc 157 nederland Peptide BPC-157(HEXADECAPEPTIDE) BPC 157 en TB 500
Description
Phase 2 trial (NEJM, 2023) The landmark Phase 2 trial, published in the New England Journal of Medicine, randomized 338 adults with obesity to receive weekly subcutaneous retatrutide at doses of 1 mg, 4 mg, 8 mg, or 12 mg, or placebo, for 48 weeks
Its gone down now to almost normal on day 11
Yes, it works exceptionally well with other regenerative treatments like HBOT and Regenerative Injection Therapy to maximize healing
As it turns out, the unmodified peptides are surprisingly harmless
